177LuPSMA in Renal Cell Carcinoma

Summary

This study aims to evaluate the efficacy and safety of 177Lu-PSMA-617 as a systemic therapy in patients with PSMA-positive advanced clear cell renal cell carcinoma (ccRCC). The name of the study drug involved in this research study is: -177Lu-PSMA-617 (a type of radioligand therapy)

Timeline

Start

2025-07-31

Primary completion

2026-12-01

Completion

2028-12-01

Publications

• Hazut Krauthammer S, Xie W, LaBrecque N, Arsenault L, Kabarame L, Shah H, Berg S, McGregor B, Serzan M, Xu W, Viswanathan SR, Wei XX, Choueiri TK, Jacene H, Ravi P. LASER: A Phase 2 Trial of 177Lu-PSMA-617 as Systemic Therapy for RCC. J Nucl Med. 2026 Apr 1;67(4):501-505. doi: 10.2967/jnumed.125.271273.

Drugs

Indications